Bio-Techne's Bumpy Ride: What's Shaking Up the Biotech World?
Bio-Techne, a company that makes tools for medical research and drug development, had a tough quarter. Their shares dropped almost 10% before the market even opened. Why? They didn't meet their sales targets. The CEO, Kim Kelderman, pointed out some good news. The U. S. academic market is stabilizi